By 9jaeye 
Tuberculosis (TB) has now overtaken COVID-19 as the world’s leading infectious killer, according to the World Health Organization (WHO). In 2023 alone, TB caused 1.25 million deaths, marking a return to its status as the primary infectious threat globally. This stark shift highlights the urgent need for renewed focus and financial support to combat TB effectively. Unlike COVID-19, which received unprecedented attention and resources, TB has consistently struggled to secure the necessary funding for prevention and treatment efforts.
The pandemic disrupted Tuberculosis programs worldwide, halting progress in detection, diagnosis, and treatment. Unfortunately, these disruptions created a resurgence in Tuberculosis cases, especially in regions that already faced high disease burdens. While progress against Tuberculosis was slow even before the pandemic, COVID-19 diverted resources and attention away from Tuberculosis, causing rates to spike. In addition, the airborne nature of Tuberculosis enables it to spread easily in crowded or poorly ventilated spaces, which makes prevention challenging. Crowded environments like prisons, hospitals, and low-income housing often become hot spots for transmission. Unlike COVID-19, where rapid vaccine development controlled the spread, TB has no equivalent support, leaving those in high-risk areas especially vulnerable.
Drug-Resistant TB: A Rising Threat
Furthermore, the situation has worsened with the rise of drug-resistant TB strains, which are now responsible for approximately 3.6% of new cases. This form of Tuberculosis does not respond to traditional antibiotics, making it more challenging and costly to treat. As new multi-drug-resistant strains emerge, the potential for TB to spread and increase mortality rates rises sharply. Responding to this threat, health organizations and pharmaceutical companies have intensified efforts to develop treatments specifically for drug-resistant Tuberculosis. For example, Johnson & Johnson introduced a promising new drug called bedaquiline. By allowing generic versions of this drug to be produced in 134 low and middle-income countries, they aim to ensure that more patients have access to effective treatment. However, the availability of these medications remains limited, further emphasizing the need for increased investment and coordination World Health Organization (WHO).
Urgent Call for Funding and Global Action
To meet the WHO’s goal of ending Tuberculosis by 2030, experts estimate that $22 billion annually is essential for TB prevention, diagnosis, and treatment worldwide. This funding could empower high-risk countries, including those in parts of Africa, Asia, and Eastern Europe, to expand their testing, treatment, and preventive programs. Nevertheless, global funding for TB remains significantly below the required levels. Without substantial investments, TB will likely continue its resurgence, reversing years of progress in global health. As a result, public health advocates urge governments, international organizations, and philanthropic groups to prioritize TB funding urgently.
With TB once again the world’s deadliest infectious disease, coordinated global action becomes more critical than ever. By prioritizing resources, fostering innovative treatments, and expanding public health infrastructure, leaders can curb TB’s spread and prevent the possibility of future outbreaks.
For more of interesting stories and Breaking News, check 9ja Eye News categories.